B. Metzler seel. Sohn & Co. Holding AG Invests $1.51 Million in DexCom, Inc. (NASDAQ:DXCM)

B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 22,578 shares of the medical device company’s stock, valued at approximately $1,514,000.

A number of other hedge funds also recently added to or reduced their stakes in DXCM. Acadian Asset Management LLC boosted its holdings in shares of DexCom by 40.3% during the 1st quarter. Acadian Asset Management LLC now owns 8,008 shares of the medical device company’s stock valued at $1,109,000 after acquiring an additional 2,299 shares during the last quarter. Advisors Asset Management Inc. boosted its position in DexCom by 13.9% in the first quarter. Advisors Asset Management Inc. now owns 14,800 shares of the medical device company’s stock worth $2,053,000 after purchasing an additional 1,809 shares during the last quarter. Steel Grove Capital Advisors LLC bought a new stake in shares of DexCom during the 1st quarter valued at about $354,000. Bellevue Group AG increased its position in shares of DexCom by 33.5% during the 1st quarter. Bellevue Group AG now owns 1,221,197 shares of the medical device company’s stock valued at $169,380,000 after purchasing an additional 306,604 shares during the last quarter. Finally, Ascent Group LLC grew its position in DexCom by 3.7% during the first quarter. Ascent Group LLC now owns 6,295 shares of the medical device company’s stock valued at $873,000 after buying an additional 222 shares during the period. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Royal Bank of Canada dropped their price target on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Stifel Nicolaus upped their price target on shares of DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, August 23rd. Wells Fargo & Company raised their price objective on shares of DexCom from $80.00 to $90.00 and gave the company an “overweight” rating in a research report on Friday, October 25th. JPMorgan Chase & Co. boosted their price objective on DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Finally, Piper Sandler restated an “overweight” rating and issued a $90.00 price target on shares of DexCom in a research note on Monday, August 26th. Seven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $104.59.

DexCom Price Performance

NASDAQ:DXCM opened at $72.83 on Friday. The firm has a market capitalization of $28.45 billion, a price-to-earnings ratio of 44.60, a PEG ratio of 2.30 and a beta of 1.17. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The business has a 50 day simple moving average of $70.54 and a 200-day simple moving average of $90.23. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00.

Insider Activity at DexCom

In related news, EVP Sadie Stern sold 426 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the sale, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at $5,217,436.65. This represents a 0.56 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. This trade represents a 0.28 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 5,431 shares of company stock worth $399,319. Company insiders own 0.30% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.